Ken Griffin Sutro Biopharma, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 16,600 shares of STRO stock, worth $23,904. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,600
Previous 2,100
690.48%
Holding current value
$23,904
Previous $7,000
328.57%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding STRO
# of Institutions
128Shares Held
59.9MCall Options Held
203KPut Options Held
33.6K-
Suvretta Capital Management, LLC New York, NY7.46MShares$10.7 Million0.57% of portfolio
-
Black Rock Inc. New York, NY6.91MShares$9.95 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.21MShares$6.06 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.64MShares$5.24 Million0.42% of portfolio
-
Vestal Point Capital, LP New York, NY2.57MShares$3.7 Million0.28% of portfolio
About SUTRO BIOPHARMA, INC.
- Ticker STRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,161,500
- Market Cap $75.1M
- Description
- Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...